- Categories
- Satellite Symposium
- Satellite Symposium
- Satellite Symposium
Redefining Treatment Paradigms for CLL Patients Pretreated with Covalent BTK Inhibitors
-
,
Boston 1-2
Endorsed by: Eli Lilly and Company
- Current Treatment Landscape in Chronic Lymphocytic Leukemia (CLL)
- Therapeutic Sequencing After Covalent BTK Inhibitor Therapy: Emerging Data and Strategies
- Pirtobrutinib (Jaypirca™): A Novel Option for Covalent BTK Inhibitor–Pretreated CLL Patients
- Clinical Experience and Development Program of Pirtobrutinib (Jaypirca™):